Sarcoma  >>  Lartruvo (olaratumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lartruvo (olaratumab) / Eli Lilly
2018-001124-20: Efficacy of Olaratumab and Re-Treatment with Doxorubicin in anthracycline pretreated, advanced soft tissue sarcoma patients.

Ongoing
2
60
Europe
Dexrazoxan, Doxorubicinhydrochlorid, Concentrate for solution for infusion, Powder for solution for infusion, Lartruvo®, CARDIOXANE®
IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Lilly Deutschland GmbH, Clinigen Healthcare Limited
locally advanced (unresectable) or metastatic soft tissue sarcoma, locally advanced (unresectable) or metastatic soft tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT01185964: A Study of Olaratumab in Soft Tissue Sarcoma

Completed
1b/2
148
US
Olaratumab, LY3012207, IMC-3G3, doxorubicin
Eli Lilly and Company
Sarcoma, Soft Tissue
08/14
04/16

Download Options